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TCT-460
Bivalirudin versus heparin during percutaneous coronary intervention:
a meta-analysis of randomized trials
Salvatore Cassese1, Robert Byrne1, Heribert Schunkert1, Peter B. Berger2,
Adnan Kastrati1
1Deutsches Herzzentrum, Munich, Germany, 2Geisinger Health System, Danville, PA
Background: Current recommendation on the use of bivalirudin in patients under-
going percutaneous coronary intervention (PCI) are mostly based on trials comparing
bivalirudin versus heparin plus planned glycoprotein IIb/IIIa inhibitor (GPI). Whether
bivalirudin is also superior to heparin alone is still not fully established. This meta-
analysis investigates the efﬁcacy and safety of bivalirudin versus heparin in patients
treated with PCI and provisional or bailout GPI use.
Methods: Scientiﬁc databases and websites were searched. The primary efﬁcacy and
safety outcomes were the 30-day incidence of death and major bleeding, respec-
tively. The secondary outcomes were the 30-day incidence of myocardial infarction
(MI), deﬁnite stent thrombosis (ST) and urgent target vessel revascularization
(TVR). Odds ratio (OR) and 95% conﬁdence interval [95% CI] served as summary
statistics.
Results: A total of 18,065 PCI-patients randomized to bivalirudin (n¼ 9,033)
versus heparin (n¼ 9,032) were studied. At 30 days, bivalirudin versus heparin
shows comparable risk of death (1.09 [0.83-1.41], p¼ 0.54), lower risk of major
bleeding (0.57 [0.40-0.80], p¼ 0.001), higher risk of deﬁnite ST (2.09 [1.26-3.47],
p¼ 0.005), comparable risk of MI (1.10 [0.83-1.46], p¼ 0.50) with a trend to-
wards a higher risk of urgent TVR (1.37 [0.96–1.96], p¼ 0.08). In particular, the
risk of acute ST (within 24 hours) is increased by bivalirudin (3.48 [1.66-7.28],
p< 0.001).
Conclusions: In patients treated with PCI, bivalirudin versus heparin does not reduce
mortality. The lower risk of major bleeding is achieved at the expense of a higher risk
of acute ST.
TCT-461
Bivalirudin Versus Unfractionated Heparin in Percutaneous Coronary
Intervention for Stable Angina: A Randomized Clinical Trial (STATUS-PCI)
Fabio Lima1, Luis Gruberg1, Usman Aslam1, Kydanis Clase1, Melissa Ramgadoo1,
Alessandra Trevisan1, Allen Jeremias1
1Stony Brook University, Stony Brook, NY
Background: Few direct comparisons between unfractionated heparin (UFH) mon-
otherapy vs. bivalirudin (Angiomax, The Medicine’s Company Inc., Parsippany, NJ)
for percutaneous coronary intervention (PCI) in patients with stable angina exists in
the modern era of dual anti-platelet therapy.
Methods: STATUS-PCI is a prospective, investigator initiated, single-center, single-
blinded, randomized 1:1 trial of UFH vs. bivalirudin in patients with stable angina
or silent ischemia on non-invasive stress testing undergoing PCI of 1 or more
>70% coronary stenosis. The primary endpoint of the study was comprised of
major and minor bleeding events (deﬁned by the REPLACE-2 trial deﬁnition)
during the index hospitalization and up to 30 days. Secondary endpoints included
major adverse cardiac events (MACE) comprising all-cause mortality, myocardial
infarction (MI), ischemia driven target vessel revascularization (TVR), and cerebral
vascular accident (CVA) and net adverse cardiac events (NACE), deﬁned as a
composite of MACE and any bleeding event at 30 days. Based on chi-square
testing with the signiﬁcance level of 0.05 and a power of 0.80, 388 patients in each
group (with continuity correction) are required to show a 50% relative decrease in
bleeding in the bivalirudin arm, assuming a 12% rate of bleeding in the control arm
(i.e. UFH).
Results: The study was halted prematurely for futility by the data safety monitoring
board after enrollment of 260 patients. There were no signiﬁcant differences in
baseline characteristics between the 2 groups. Radial access was used in 28.5% vs.
23.4% (p¼0.348) and closure devices were used in 50.8% vs. 55.6% (p¼0.447) in the
UFH and bivalirudin groups, respectively. The primary endpoint occurred in 22 pa-
tients (8.5%) without a signiﬁcant difference between the groups (11 [8.9%] vs. 11
[8.0%], p¼0.808). MACE at 30 days occurred in 0 vs. 3 (2.2%) [p¼0.10] and NACE
in 11 (8.9%) vs. 14 (10.2%) [p¼0.71] patients in the UFH and bivalirudin groups,
respectively.
Conclusions: Among patients with stable ischemic heart disease undergoing PCI on
dual anti-platelet therapy, there was no signiﬁcant difference between UFH and
bivalirudin with respect to bleeding events or MACE at 30 days.JACC Vol 64/11/Suppl B j September 13–17, 2014 j TCT Abstracts/PhTCT-462
Heparin versus Bivalirudin in patients undergoing Percutaneous Coronary
Intervention
Ahmed Rehmani1, Chris Judkins1, Edmund Lee1, Michael Nguyen1, Alan Whelan1,
Carl Schultz1
1Fremantle Hospital, Fremantle, WA
Background: Anti-platelet and anti-coagulant adjunctive therapies are associated
with an increased risk of major bleeding that adversely impacts on clinical
outcomes. Objective: To retrospectively assess the in hospital MACE and major
bleeding in patients with acute coronary syndrome (ACS) undergoing percutaneous
coronary intervention(PCI) received either unfractionated heparin (UFH) or
Bivalirudin.
Methods: Consecutive patients undergoing PCI for ACS at Fremantle Hospital
from August 2008 to December 2013 were identiﬁed. All patients were pre-treated
with dual antiplatelet therapy. Patients received intravenous UFH (50-100IU/kg)
to achieve activated coagulation time 250 to 300s or Bivalirudin (bolus 0.75 mg/kg
and Infusion 1.75 mg/kg/hr). Adjunctive glycoprotein IIbIIIa was given at the
discretion of the operator. In-hospital MACE and bleeding events were identiﬁed
from systematic review of case notes after hospital discharge and from PCI
database.
Results: 3371 patients were identiﬁed, 1741 received UFH and 1631 received
Bivalirudin. Mean age was 62.3 years in both groups (p¼0.575). Female gender was
24% vs. 26% (p¼0.10) , current smoking 66% vs. 70% (p¼0.53, and diabetes 25%
vs. 26% (p¼0.62) in UFH vs. Bivalirudin groups. 85% of patients received Clo-
pidogrel, 8% Ticagrelor and 4% Prasugrel in both groups(p¼ ns). In UFH vs.
Bivalirudin groups STEMI presentation was 28% vs. 19%, NSTEMI/USA 51% vs.
58% and elective 19% vs. 23% respectively. Trans-femoral access was used in 93%
vs. 92% (p¼0.41). More patients received GPIIbIIIa antagonists in the UFH group
(30.2% vs. 3.4%; p< 0.001). Pre-discharge stent thrombosis were noted in 1.0%
with UFH vs. 0.5% with Bivalirudin(p¼0.20). The incidence of in hospital MACE
was similar and the incidence of BARC 1(Bleeding Academic Research consortium)
was1.8% in UFH group vs. 1.1% bivalirudin group. BARC2 bleeding was 1.5%
Bivalirudin vs. UFH 2.1%(p¼0.228). BARC 5 major bleeding was 0.0% in both
groups.
Conclusions: In this PCI cohort, UFH compared with Bivalirudin was not associated
with a high incidence of in hospital MACE and major bleeding despite a signiﬁcantly
higher rate of GPIIbIIIa antagonist treatment in the UFH group.
TCT-463
Does Routine Post-Procedural Anticoagulation Reduce Acute Stent
Thrombosis after Bivalirudin Anticoagulation During Primary PCI? The
HORIZONS-AMI Trial
Mahesh V. Madhavan1, George Dangas2, Philippe Genereux3, Ke Xu4,
Roxana Mehran2, Gregg W. Stone3
1Columbia University Medical Center, New York, NY, 2Icahn School of Medicine at
Mount Sinai, New York, NY, 3Columbia University Medical Center and the
Cardiovascular Research Foundation, New York, United States, 4Cardiovascular
Research Foundation, New York, NY
Background: The rate of acute (24 hours) stent thrombosis (ST) is increased with
bivalirudin anticoagulation (AC) during primary percutaneous coronary intervention
(PCI) for ST-segment elevation myocardial infarction (STEMI) compared to heparin
plus the routine use of a glycoprotein IIb/IIIa inhibitor. Prior studies suggest that pre-
PCI unfractionated heparin (UFH) may protect against acute ST, presumably due to its
longer half-life. In this regard, whether the routine use of post-PCI AC is able to
prevent ST in this setting is unknown. We therefore evaluated outcomes after routine
AC prophylaxis following primary PCI in bivalirudin-treated pts from the HORI-
ZONS-AMI trial.
Methods: 1,445 pts who received bivalirudin during primary PCI were grouped ac-
cording to use of pre-PCI UFH, post-PCI AC for routine prophylaxis, both, or neither.
Acute and 30-day rates of deﬁnite or probable ST were assessed using propensity-
adjusted multivariable analysis.
Results: 948 pts (65.6%) received pre-PCI UFH, 436 (30.2%) received post-PCI AC
for routine prophylaxis (for median 4.0 days), and 386 (26.7%) received neither. 623
pts (43.1%) received only pre-procedural UFH and 111 (7.7%) received only post-PCI
AC for routine prophylaxis. ST occurred in 13 pts (0.9%) within the ﬁrst 24 hours post
PCI and in 27 pts (1.9%) within 30 days. By multivariate analysis, post-PCI AC for
routine prophylaxis was not associated with reduced acute or 30-day ST, regardless of
whether or not pts also received pre-PCI UFH (Table).
Conclusions: In this large-scale study, post-PCI AC for routine prophylaxis following
bivalirudin monotherapy during primary PCI was not associated with a reduction in
acute or 30-day ST.armacotherapy - Procedural Anticoagulants B135
Table. Rates of Stent Thrombosis
Any post-PCI AC
for routine
prophylaxis
(N¼436)
No post-PCI AC for
routine
prophylaxis
(N¼1,009)
Adjusted
HR [95%
CI]
Adjusted
p-Value
Acute
(24 hour)
stent
thrombosis
3 (0.7) 10 (1.0) 0.65 [0.13,
3.18]
0.59
Thirty-day
stent
thrombosis
7 (1.7) 20 (2.1) 0.97 [0.37,
2.53]
0.95
Post-PCI AC for
routine
prophylaxis with
pre-PCI UFH
(N¼325)
Pre-PCI UFH with
no post-PCI AC for
routine prophylaxis
(N¼623)
Unadjusted
HR [95%
CI]
Unadjusted
p-Value
Acute
(24 hour)
stent
thrombosis
2 (0.6) 3 (0.5) 1.28 [0.21,
7.68]
0.78
Thirty-day
stent
thrombosis
5 (1.6) 8 (1.3) 1.20 [0.39,
3.65]
0.75
Only post-PCI AC
for routine
prophylaxis with
no pre-PCI UFH
(N¼111)
No pre-PCI UFH or
post-PCI AC for
routine prophylaxis
(N¼386)
Unadjusted
HR [95%
CI]
Unadjusted
p-Value
Acute
(24 hour)
stent
thrombosis
1 (0.9) 7 (1.9) 0.50 [0.06,
4.02]
0.50
Thirty-day
stent
thrombosis
2 (1.9) 12 (3.3) 0.57 [0.13,
2.55]
0.46
Values presented as n (%). Stent thrombosis was classiﬁed according to the Academic
Research Consortium deﬁnition of deﬁnite or probable. AC ¼ anticoagulation; PCI ¼ percu-
taneous coronary intervention; UFH ¼ unfractionated heparin.
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Intracoronary Bivalirudin Bolus During Primary Angioplasty Improves
Postprocedural Angiographic Flow and Myocardial Reperfusion Indexes
Alessandro Lupi1, Andrea Rognoni1, Gioel G. Secco2, Angelo S. Bongo1
1AOU Maggiore della Carità, Novara, Italy, 2University of Eastern Piedmont,
Novara, Italy
Background: Bivalirudin efﬁcacy in the very ﬁrst hours after primary PCI
has been questioned, due to increased acute stent thrombosis rates. Intracoronary
administration of the bivalirudin bolus might furnish an extremely high
local drug concentration without changing the global dose administered to the
patient, with a potential favorable effect over the pro-thrombotic milieu of the
infarct related artery. Thus we prospectively investigated the feasibility and
safety of intracoronary bivalirudin bolus administration during primary percuta-
neous coronary interventions (PCI), comparing it with the standard intravenous
route.
Methods: In 245 consecutive patients treated with primary PCI we administered
intracoronary bivalirudin bolus followed by standard intravenous infusion. Post-
procedural coronary blood ﬂow indexes and clinical reperfusion markers of these
patients were compared with a propensity score-matched cohort of primary PCI pa-
tients treated with standard intravenous bivalirudin bolus plus infusion.
Results: Our study suggests safety similar bleeding episodes were observed in the two
groups. However we observed better TIMI frame count values (14.7 vs 17.9,
P¼0.001), higher rates of  70% ST resolution (72.7 vs 60.0%, p¼0.004) and lower
postprocedural peak CK-MB levels (188.3  148.7 vs 242.1  208.1 Ui/dL,
P¼0.025) in the intracoronary bolus group. Acute stent thrombosis was observed only
in 3 cases, all in the intravenous bolus group (P¼NS). These results were substantially
conﬁrmed when the analysis was restricted to patients with evidence of an occluded
infarct related artery before PCI.
Conclusions: In the population studied intracoronary bivalirudin bolus during primary
PCI is safe and might improve results obtained through the standard intravenous route
over postprocedural coronary ﬂow and clinical myocardial reperfusion.B136 JACC Vol 64/11/Suppl B j September 13–1TCT-465
Safety and efﬁcacy of intracoronary bivalirudin administration during primary
angioplasty in comparison with a standard treatment with heparin and
provisional GP2b3a inhibitors
Alessandro Lupi1, Gioel G. Secco2, Andrea Rognoni1, Italo Porto3,
Maurizio Lazzero1, Angelo S. Bongo1
1AOU Maggiore della Carità, Novara, Italy, 2University of Eastern Piedmont,
Novara, Italy, 3San Donato Hospital, Arezzo, Italy
Background: Bivalirudin efﬁcacy in the very ﬁrst hours after primary PCI has been
questioned, due to increased acute stent thrombosis rates. Intracoronary adminis-
tration of the bivalirudin bolus might furnish an extremely high local drug con-
centration without changing the global dose administered to the patient, with a
potential favorable effect over the pro-thrombotic milieu of the infarct related artery.
We prospectively investigated the feasibility and safety of intracoronary bivalirudin
bolus administration during primary percutaneous coronary interventions (PCI),
comparing this strategy with the standard treatment based upon unfractionated
heparin (UFH) with provisional GP2B3A inhibitors (GPI) given through the intra-
venous route.
Methods: In 273 consecutive patients treated with primary PCI we administered
intracoronary bivalirudin bolus followed by standard intravenous infusion.
Postprocedural coronary blood ﬂow indexes and clinical reperfusion markers of
these patients were compared with a propensity score-matched cohort of primary
PCI patients treated with standard treatment with intravenous UFH 70Ui/Kg
(eventually with supplementary boluses to achieve an ACT>250sec) plus pro-
visional GPI.
Results: In the intracoronary bivalirudin group we observed better TIMI frame count
values (14.86.5 vs 16.99.3, P¼0.002), higher rates of  70% ST resolution (72.1
vs 44.5%, p¼0.001), lower incidence of no-reﬂow (7.0 vs 13.5%, p< 0.011) and a
trend for lower postprocedural peak CK-MB levels (140.0 [53.7-235.5] vs 159.2
[64.3-269.9] Ui/dL, p¼0.06). Moreover acute stent thrombosis (< 24h after PCI) was
observed in 11 cases, all in the UFH/GPI group (p¼0.009). Intracoronary bivalirudin
administration was safe, with less internal bleedings (3.7 vs 11.2%, p¼0.001) and less
need for transfusion (4.6 vs 1.1, p¼0.012). The results were substantially conﬁrmed
when the analysis was restricted to patients with an occluded infarct related artery
before PCI.
Conclusions: In the population studied intracoronary bivalirudin during primary PCI
was safe and might improve postprocedural coronary ﬂow, clinical myocardial
reperfusion and acute stent thrombosis rates, in comparison with the UFH plus pro-
visional GPI treatment.
TCT-466
Bivalirudin Is Associated With Improved In-Hospital Outcomes After Peripheral
Arterial Interventions: An Observational Analysis On 23,934 Patients From The
PREMIER Hospital Database
Carey D. Kimmelstiel1, Duane Pinto2, Andrew Weintraub3, George Dangas4,
Weihong Fan5, Jayne Prats6, Efthymios N. Deliargyris5, Barry T. Katzen7
1Tufts Medical Center, Boston, United States, 2Beth Israel Deaconess Medical Center,
Boston, United States, 3Tufts Medical Center, Boston, MA, 4Mount Sinai, New York,
New York, NY, 5The Medicines Company, Parsippany, NJ, 6The Medicines Company,
Parsippany, NJ, 7Baptist Cardiac and Vascular Institute, Miami, FL
Background: Bivalirudin has been shown to reduce bleeding complications and
improve clinical outcomes in percutaneous coronary interventions but has not been
well studied in peripheral arterial interventions (PAI). We sought to evaluate the ef-
ﬁcacy and safety of bivalirudin as compared with unfractionated heparin (UFH) in
patients undergoing PAI by evaluating in-hospital outcomes from a large, real-world,
US hospital database of over 600 hospitals.
Methods: We identiﬁed all patients (n¼23,934) entered from 1/08-12/12 in the
PREMIER hospital database following PPI of the extremities and who were treated
with bivalirudin or UFH. In-hospital outcomes that were compared according to
treatment included death , myocardial infarction (MI), transfusion, stroke, amputation,
Major Adverse Cardiac Events (MACE: death, MI, stroke or amputation) and Net
Adverse Cardiac Events (NACE: MACE and transfusion). Propensity score matching
(PSM) was performed to control for selection bias.
Results: In-hospital outcomes for both the unadjusted population and the 3,649 PSM
pairs are shown in the Table. After PSM, bivalirudin was still associated with
signiﬁcantly lower rates of death, transfusion, MACE and NACE compared with
UFH. Linear regression modeling conﬁrmed these ﬁndings. Subgroup analysis in the
PSM population showed consistent treatment effect for all outcomes among
subgroups.7, 2014 j TCT Abstracts/Pharmacotherapy - Procedural Anticoagulants
